37 results about "Gonadotrophin release hormone" patented technology

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.

An artificial decapeptide for inducing vitellogenesis in fish, being an analogue of gonadotropin-releasing hormone of chicken is set forth in SEQ ID NO: 2. The artificial decapeptide can be further developed and manufactured into a preparation, which is capable of inducing vitellogenesis in fish. With the implantation of the preparation into body cavity or body wall of bony fish, the induction of vitellogenesis and ovum maturation in bony fish can be successfully achieved.

The invention provides a drug sustained release microsphere, a preparation method and an application thereof. The preparation method comprises the following steps: filtering an 'internal water phase / oil phase / external water phase' pre-emulsion solution with a micro-pore film, and then removing a solvent during a curing process, washing and drying, thereby acquiring the drug sustained release microsphere, wherein a gonadotrophin releasing hormone aqueous solution is served as the internal water phase. The preparation method provided by the invention is simple. The drug sustained release microsphere prepared according to the invention has uniform and controllable size, different batches of products are high in repeatability and the drug sustained release microsphere is easy for industrial production.

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.

A method for non-surgical neutering or castration of a non-human mammal for AAV-mediated delivery of an anti-GnRH polypeptide to a non-human animal is described. More particularly, the animal is administered an adeno-associated virus (AAV) vector having an AAV capsid having packaged therein nucleic acid sequences comprising an AAV 5′ inverted terminal repeat (ITR), a sequence encoding a polypeptide which specifically binds gonadotropin releasing hormone (GnRH) under control of regulatory sequences which direct expression of the polypeptide, and an AAV 3′ ITR. A composition comprising the AAV-anti-GnRH may also be used for inhibiting tumor growth in a mammal with a cancer responsive to gonadal steroid hormones.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist.

A compound of the formula:wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.

The invention provides a novel recombination targeting fusion protein GnRH-TNF alpham which is integrated from gonadotrophin releasing hormone (GnRH-A) and recombinant mutant human tumor necrosis factor alpha (TNF alpha), the targeting fusion protein has destroying action to the tumor cells endured by the prototype TNF alpha. The invention also provides the DNA sequence of the recombinant target fusion protein GnRH-TNFam and its expression recombinants.

The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.

The present invention relates to the use of a gonadotropin-releasing hormone (including GnRH I, a GnRH I analogue, GnRH II, or a GnRH II analogue) as adjuvant immunotherapeutic.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

The invention relates to a fusion protein mutant capable of directionally killing tumour cells, which consists of an orienting part and an effect part, wherein the orienting part consists of gonadotropin releasing hormone (GnRH), the effect part consists of cytotoxin, and the fusion protein mutant has the characteristics that the tumour cells excessively expressing GnRH receptors can be directionally reached and killed.

The invention provides a novel recombination targeting fusion protein GnRH-TNF alpham which is integrated from gonadotrophin releasing hormone (GnRH-A) and recombinant mutant human tumor necrosis factor alpha (TNF alpha), the targeting fusion protein has destroying action to the tumor cells endured by the prototype TNF alpha. The invention also provides the DNA sequence of the recombinant target fusion protein GnRH-TNFam and its expression recombinants.

The invention belongs to the technical field of the molecular biology and describes a fusion vaccine containing an encoded immunocontraceptive protein gonadotropin-releasing hormone (GnRH) and a heterologous defensin polypeptide (HDP). The invention discloses a method for construction, transformation expression and purification of the recombinant GnRH-HDP fusion protein vaccine. Through inoculation of animals, a contraceptive peptide-specific antibody is produced through immunization and controls the animal fertility. The GnRH-HDP defensin immunogenic composition can effectively control the fertility of the animals.

The invention provides a preparation for controlling ovulation of equine animals and a method for controlling ovulation. The preparation comprises a gonadotropin-releasing hormone analogue and a degradable slow-release carrier in the animal body. By preparing the gonadotropin-releasing hormone as a slow-release preparation, its half-life in the body is effectively prolonged, so that the preparation can play a long-term, efficient and stable role in promoting ovulation. By injecting the preparation of the present invention, more than 96% of mares and donkeys ovulate within 48 hours, and the ovulation time of more than 96% of the animals is controlled within 8 hours, realizing efficient ovulation control of equine animals and significantly improving Breeding pregnancy rates in equines. The ovulation control method of the present invention is easy to operate, low in cost and remarkable in control effect, does not produce any harmful effects on the animal itself and its products, and can be widely used in mating species of equine animals, artificial insemination, embryo transfer and timed insemination, Has broad market prospects.

The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or G, and even more particularly, X is E or Q. Thus, a preferred amino acid sequence for the peptide is GPRLGYSWHE. The peptide may optionally include one or more additional D-amino acids at its N- or C-terminus, for example a cysteine residue or a series of linker amino acids, such as a plurality of glycine amino acid residues. Thus, a second preferred amino acid sequence for the peptide is GPRLGYSWHEC, which includes a cysteine residue at the C-terminus for conjugation purposes. The invention also describes a vaccine composition for use in controlling fertility, heat, contraception and / or treating sex hormone-related diseases, and a method for controlling and or treating fertility and sex hormone-related diseases.

The invention provides a method for synthesizing salmon gonadotropin releasing hormone by polypeptide solid-liquid combination. The method for synthesizing the salmon gonadotropin releasing hormone bypolypeptide solid-liquid combination comprises the following steps: 1) synthesizing a compound 1: Boc-Pyr-His (Boc)-Trp (Boc)-Ser (tBu)-Tyr (tBu)-Gly-Trp (Boc)-Leu-OH by a polypeptide solid phase method; 2) synthesizing a compound 2: H-Pro-Gly-NH2 by a polypeptide liquid phase method; 3) synthesizing a compound 3: Boc-Pyr-His (Boc)-Trp (Boc)-Ser (tBu)-Tyr (tBu)-Gly-Trp (Boc)-Leu-Pro-Gly-NH2 in aliquid phase; and 4) synthesizing a salmon gonadotropin releasing hormone crude product: Pyr-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH2. According to the method provided by the invention, CTC resin is used for synthesizing fragments for the first time, and the liquid phase method is combined to synthesize the salmon gonadotropin releasing hormone; the CTC resin synthesized fragments can be conveniently and automatically produced; the CTC resin can be recycled, so that the cost of solid phase synthesis by Rink resin in literature is greatly reduced, and the price of the Rink resin is much higher than that of the CTC resin and cannot be recycled; the method is suitable for large-scale industrial production and does not have a severe chemical reaction; and compared with a process reported in theliterature at present, the method provided by the invention reduces the production cost.

The invention discloses the GnRH antigen and its application in the castration effect and meat quality of bulls by active immunization. The invention provides a GnRH derivative, which is to insert a short peptide capable of forming an α-helix between multiple GnRH antigen monomers in series to obtain a GnRH derivative; the GnRH antigen monomer is the GnRH amino acid sequence of GnRH The 6th glycine is replaced by D-lysine to obtain a polypeptide. The active immunization of male rats and bulls with the GnRH Erkuzi α-helix vaccine screened out in this experiment can partially or completely lose the biological activity of testosterone, play a role in immune castration, and have a better effect of boosting immunity. There is a certain improvement.

The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e.g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea syndrome, multilocular ovary syndrome, pimples etc, or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.